Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

Development of a person-centered interdisciplinary plan-of-care program for dialysis.

Dorough A, Forfang D, Murphy SL, Mold JW, Kshirsagar AV, DeWalt DA, Flythe JE.

Nephrol Dial Transplant. 2020 Feb 21. pii: gfaa018. doi: 10.1093/ndt/gfaa018. [Epub ahead of print]

PMID:
32083669
2.

Five-Year Outcomes of Pulmonary Hypertension with and without Elevated Left Atrial Pressure in Patients Evaluated for Kidney Transplantation.

Caughey MC, Detwiler RK, Sivak JA, Rose-Jones LJ, Kshirsagar AV, Hinderliter AL.

Transplantation. 2019 Dec 26. doi: 10.1097/TP.0000000000003068. [Epub ahead of print]

PMID:
31880752
3.

Transplant First, Dialysis Last.

Kshirsagar AV, Kibbe MR, Gerber DA.

JAMA Surg. 2019 Sep 19. doi: 10.1001/jamasurg.2019.4286. [Epub ahead of print] No abstract available.

PMID:
31536117
4.

Long-Term Risks of Intravenous Iron in End-Stage Renal Disease Patients.

Kshirsagar AV, Li X.

Adv Chronic Kidney Dis. 2019 Jul;26(4):292-297. doi: 10.1053/j.ackd.2019.05.001. Review.

PMID:
31477259
5.

Thirty-year risk of ischemic stroke in individuals with sickle cell trait and modification by chronic kidney disease: The atherosclerosis risk in communities (ARIC) study.

Caughey MC, Derebail VK, Key NS, Reiner AP, Gottesman RF, Kshirsagar AV, Heiss G.

Am J Hematol. 2019 Dec;94(12):1306-1313. doi: 10.1002/ajh.25615. Epub 2019 Sep 10.

PMID:
31429114
6.

Association of sickle cell trait with measures of cognitive function and dementia in African Americans.

Chen N, Caruso C, Alonso A, Derebail VK, Kshirsagar AV, Sharrett AR, Key NS, Gottesman RF, Grove ML, Bressler J, Boerwinkle E, Windham BG, Mosley TH Jr, Hyacinth HI.

eNeurologicalSci. 2019 Jul 22;16:100201. doi: 10.1016/j.ensci.2019.100201. eCollection 2019 Sep.

7.

Safety of Dynamic Intravenous Iron Administration Strategies in Hemodialysis Patients.

Li X, Cole SR, Kshirsagar AV, Fine JP, Stürmer T, Brookhart MA.

Clin J Am Soc Nephrol. 2019 May 7;14(5):728-737. doi: 10.2215/CJN.03970318. Epub 2019 Apr 15.

PMID:
30988164
8.

A Pivot Towards Moderating Intravenous Iron Therapy in Hemodialysis.

Li X, Kshirsagar AV.

Am J Kidney Dis. 2019 Jul;74(1):138-140. doi: 10.1053/j.ajkd.2019.01.016. Epub 2019 Mar 22. No abstract available.

PMID:
30910372
9.

Excess Readmission-Based Penalty: Is Arthroplasty Different From the Other Outcomes?

Manickam RN, Memtsoudis SG, Mu Y, Kim J, Kshirsagar AV, Bang H.

J Surg Orthop Adv. Winter 2018;27(4):286-294.

10.

Assessing Residual Bias in Estimating Influenza Vaccine Effectiveness: Comparison of High-dose Versus Standard-dose Vaccines.

Butler AM, Layton JB, Krueger WS, Kshirsagar AV, McGrath LJ.

Med Care. 2019 Jan;57(1):73-78. doi: 10.1097/MLR.0000000000001018.

PMID:
30422840
11.

Patient Satisfaction Is Associated With Dialysis Facility Quality and Star Ratings.

Kshirsagar AV, Tabriz AA, Bang H, Lee SD.

Am J Med Qual. 2019 May/Jun;34(3):243-250. doi: 10.1177/1062860618796310. Epub 2018 Sep 18.

12.

High-dose influenza vaccine use among patients receiving hemodialysis in the United States, 2010-2013.

McGrath LJ, Layton JB, Krueger WS, Kshirsagar AV, Butler AM.

Vaccine. 2018 Oct 1;36(41):6087-6094. doi: 10.1016/j.vaccine.2018.08.079. Epub 2018 Sep 6.

13.

Data concordance between ESRD Medical Evidence Report and Medicare claims: is there any improvement?

Mu Y, Chin AI, Kshirsagar AV, Bang H.

PeerJ. 2018 Jul 27;6:e5284. doi: 10.7717/peerj.5284. eCollection 2018.

14.

Primary prevention of chronic kidney disease through population-based strategies for blood pressure control: The ARIC study.

Hardy ST, Zeng D, Kshirsagar AV, Viera AJ, Avery CL, Heiss G.

J Clin Hypertens (Greenwich). 2018 Jun;20(6):1018-1026. doi: 10.1111/jch.13311. Epub 2018 May 23.

15.

Regional and Temporal Variations in Comorbidity Among US Dialysis Patients: A Longitudinal Study of Medicare Claims Data.

Mu Y, Chin AI, Kshirsagar AV, Zhang Y, Bang H.

Inquiry. 2018 Jan-Dec;55:46958018771163. doi: 10.1177/0046958018771163.

16.

Rest Easy with Intravenous Iron for Dialysis Patients? High Dose IV Iron Safety.

Li X, Kshirsagar AV.

Clin J Am Soc Nephrol. 2018 Mar 7;13(3):363-365. doi: 10.2215/CJN.00930118. Epub 2018 Feb 20. No abstract available.

17.

Association Between Gestational Diabetes and Incident Maternal CKD: The Coronary Artery Risk Development in Young Adults (CARDIA) Study.

Dehmer EW, Phadnis MA, Gunderson EP, Lewis CE, Bibbins-Domingo K, Engel SM, Jonsson Funk M, Kramer H, Kshirsagar AV, Heiss G.

Am J Kidney Dis. 2018 Jan;71(1):112-122. doi: 10.1053/j.ajkd.2017.08.015. Epub 2017 Nov 8.

18.

Area-level poverty, race/ethnicity & dialysis star ratings.

Kshirsagar AV, Manickam RN, Mu Y, Flythe JE, Chin AI, Bang H.

PLoS One. 2017 Oct 17;12(10):e0186651. doi: 10.1371/journal.pone.0186651. eCollection 2017.

19.

SPIRIT trial: A phase III pragmatic trial of an advance care planning intervention in ESRD.

Song MK, Unruh ML, Manatunga A, Plantinga LC, Lea J, Jhamb M, Kshirsagar AV, Ward SE.

Contemp Clin Trials. 2018 Jan;64:188-194. doi: 10.1016/j.cct.2017.10.005. Epub 2017 Oct 6.

20.

Psychosocial Factors and 30-Day Hospital Readmission among Individuals Receiving Maintenance Dialysis: A Prospective Study.

Flythe JE, Hilbert J, Kshirsagar AV, Gilet CA.

Am J Nephrol. 2017;45(5):400-408. doi: 10.1159/000470917. Epub 2017 Apr 14.

21.

Safety of intravenous iron in hemodialysis patients.

Li X, Kshirsagar AV, Brookhart MA.

Hemodial Int. 2017 Jun;21 Suppl 1:S93-S103. doi: 10.1111/hdi.12558. Epub 2017 Apr 3. Review.

22.

Area-Level Poverty and Excess Hospital Readmission Ratios.

Manickam RN, Mu Y, Kshirsagar AV, Bang H.

Am J Med. 2017 Apr;130(4):e153-e155. doi: 10.1016/j.amjmed.2016.08.047. No abstract available.

23.

Sickle cell trait is not associated with an increased risk of heart failure or abnormalities of cardiac structure and function.

Bello NA, Hyacinth HI, Roetker NS, Seals SR, Naik RP, Derebail VK, Kshirsagar AV, Key NS, Wilson JG, Correa A, Adams RJ, Egede LD, Longstreth WT Jr, Choudhary G, Gee BE, Hughes AL, Shah AM, Manson JE, Allison M, Burke GL, Folsom AR, Carty CL, Reiner AP, Solomon SD, Konety SH.

Blood. 2017 Feb 9;129(6):799-801. doi: 10.1182/blood-2016-08-705541. Epub 2016 Dec 8. No abstract available.

24.

What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: Balancing Benefits and Safety with Intravenous Iron Treatment.

Alan Brookhart M, Li X, Kshirsagar AV.

Semin Dial. 2017 Jan;30(1):25-27. doi: 10.1111/sdi.12550. Epub 2016 Oct 20. No abstract available.

25.

Oxygen Saturation of Retinal Vessels in All Stages of Diabetic Retinopathy and Correlation to Ultra-Wide Field Fluorescein Angiography.

Guduru A, Martz TG, Waters A, Kshirsagar AV, Garg S.

Invest Ophthalmol Vis Sci. 2016 Oct 1;57(13):5278-5284. doi: 10.1167/iovs.16-20190.

PMID:
27723894
26.

Predictors of 30-Day Hospital Readmission among Maintenance Hemodialysis Patients: A Hospital's Perspective.

Flythe JE, Katsanos SL, Hu Y, Kshirsagar AV, Falk RJ, Moore CR.

Clin J Am Soc Nephrol. 2016 Jun 6;11(6):1005-14. doi: 10.2215/CJN.11611115. Epub 2016 May 5.

27.

Patients with primary membranous nephropathy are at high risk of cardiovascular events.

Lee T, Derebail VK, Kshirsagar AV, Chung Y, Fine JP, Mahoney S, Poulton CJ, Lionaki S, Hogan SL, Falk RJ, Cattran DC, Hladunewich M, Reich HN, Nachman PH.

Kidney Int. 2016 May;89(5):1111-1118. doi: 10.1016/j.kint.2015.12.041. Epub 2016 Feb 26.

28.

Ecological Factors Predict Transition Readiness/Self-Management in Youth With Chronic Conditions.

Javalkar K, Johnson M, Kshirsagar AV, Ocegueda S, Detwiler RK, Ferris M.

J Adolesc Health. 2016 Jan;58(1):40-6. doi: 10.1016/j.jadohealth.2015.09.013.

PMID:
26707228
29.

Dynamics of cinacalcet use and biochemical control in hemodialysis patients: a retrospective New-user cohort design.

Reams BD, Dluzniewski PJ, Do TP, Yue SV, Bradbury BD, Kshirsagar AV, Brookhart MA.

BMC Nephrol. 2015 Oct 29;16:175. doi: 10.1186/s12882-015-0174-6.

30.

Comparative Effectiveness of Iron and Erythropoiesis-Stimulating Agent Dosing on Health-Related Quality of Life in Patients Receiving Hemodialysis.

Freburger JK, Ellis AR, Wang L, Butler AM, Kshirsagar AV, Winkelmayer WC, Brookhart MA.

Am J Kidney Dis. 2016 Feb;67(2):271-82. doi: 10.1053/j.ajkd.2015.09.011. Epub 2015 Oct 23.

PMID:
26508682
31.

Trends in Anemia Management in Hemodialysis Patients with Cancer.

Butler AM, Kshirsagar AV, Olshan AF, Nielsen ME, Wheeler SB, Brookhart MA.

Am J Nephrol. 2015;42(3):206-15. doi: 10.1159/000440771. Epub 2015 Oct 7.

32.

Comparative Short-term Safety of Sodium Ferric Gluconate Versus Iron Sucrose in Hemodialysis Patients.

Brookhart MA, Freburger JK, Ellis AR, Winkelmayer WC, Wang L, Kshirsagar AV.

Am J Kidney Dis. 2016 Jan;67(1):119-27. doi: 10.1053/j.ajkd.2015.07.026. Epub 2015 Sep 16.

PMID:
26385819
33.

Periodontal Disease and CKD-Associated Morbidity: Is There Now Enough Evidence to Move From Observation to Intervention?

Kshirsagar AV, Grubbs V.

Am J Kidney Dis. 2015 Aug;66(2):181-3. doi: 10.1053/j.ajkd.2015.05.009. No abstract available.

PMID:
26210722
34.

Nursing Intervention Aimed at Improving Self-Managementfor Persons with Chronic Kidney Disease in North Carolina Medicaid: A Pilot Project.

Vann JC, Hawley J, Wegner S, Falk RJ, Harward DH, Kshirsagar AV.

Nephrol Nurs J. 2015 May-Jun;42(3):239-55; quiz 256.

PMID:
26207285
35.

Statin initiation and acute kidney injury following elective cardiovascular surgery: a population cohort study in Denmark†.

Layton JB, Hansen MK, Jakobsen CJ, Kshirsagar AV, Andreasen JJ, Hjortdal VE, Rasmussen BS, Simpson RJ, Brookhart MA, Christiansen CF.

Eur J Cardiothorac Surg. 2016 Mar;49(3):995-1000. doi: 10.1093/ejcts/ezv246. Epub 2015 Jul 16.

PMID:
26188012
36.

Association Between Periodontal Disease and Kidney Function Decline in African Americans: The Jackson Heart Study.

Grubbs V, Vittinghoff E, Beck JD, Kshirsagar AV, Wang W, Griswold ME, Powe NR, Correa A, Young B.

J Periodontol. 2015 Oct;86(10):1126-32. doi: 10.1902/jop.2015.150195. Epub 2015 Jun 25.

37.

Associations of Posthemodialysis Weights above and below Target Weight with All-Cause and Cardiovascular Mortality.

Flythe JE, Kshirsagar AV, Falk RJ, Brunelli SM.

Clin J Am Soc Nephrol. 2015 May 7;10(5):808-16. doi: 10.2215/CJN.10201014. Epub 2015 Apr 10.

38.

Cancer incidence among US Medicare ESRD patients receiving hemodialysis, 1996-2009.

Butler AM, Olshan AF, Kshirsagar AV, Edwards JK, Nielsen ME, Wheeler SB, Brookhart MA.

Am J Kidney Dis. 2015 May;65(5):763-72. doi: 10.1053/j.ajkd.2014.12.013. Epub 2015 Feb 7.

39.

Bile cast nephropathy.

Jain K, Gupta A, Singh HK, Nickeleit V, Kshirsagar AV.

Kidney Int. 2015 Feb;87(2):484. doi: 10.1038/ki.2014.233. No abstract available.

40.

Prospective study of sickle cell trait and venous thromboembolism incidence.

Folsom AR, Tang W, Roetker NS, Kshirsagar AV, Derebail VK, Lutsey PL, Naik R, Pankow JS, Grove ML, Basu S, Key NS, Cushman M.

J Thromb Haemost. 2015 Jan;13(1):2-9. doi: 10.1111/jth.12787. Epub 2014 Dec 11.

41.

Association of sickle cell trait with chronic kidney disease and albuminuria in African Americans.

Naik RP, Derebail VK, Grams ME, Franceschini N, Auer PL, Peloso GM, Young BA, Lettre G, Peralta CA, Katz R, Hyacinth HI, Quarells RC, Grove ML, Bick AG, Fontanillas P, Rich SS, Smith JD, Boerwinkle E, Rosamond WD, Ito K, Lanzkron S, Coresh J, Correa A, Sarto GE, Key NS, Jacobs DR, Kathiresan S, Bibbins-Domingo K, Kshirsagar AV, Wilson JG, Reiner AP.

JAMA. 2014 Nov 26;312(20):2115-25. doi: 10.1001/jama.2014.15063.

42.

Comparative short-term safety of bolus versus maintenance iron dosing in hemodialysis patients: a replication study.

Freburger JK, Ellis AR, Kshirsagar AV, Wang L, Brookhart MA.

BMC Nephrol. 2014 Sep 22;15:154. doi: 10.1186/1471-2369-15-154.

43.

Estimation of biomarker distributions using laboratory data collected during routine delivery of medical care.

Brookhart MA, Todd JV, Li X, Reams BD, Pate V, Kshirsagar AV.

Ann Epidemiol. 2014 Oct;24(10):754-61. doi: 10.1016/j.annepidem.2014.07.013. Epub 2014 Aug 6.

44.

Sickle cell trait and incident ischemic stroke in the Atherosclerosis Risk in Communities study.

Caughey MC, Loehr LR, Key NS, Derebail VK, Gottesman RF, Kshirsagar AV, Grove ML, Heiss G.

Stroke. 2014 Oct;45(10):2863-7. doi: 10.1161/STROKEAHA.114.006110. Epub 2014 Aug 19.

45.

Evaluation of the Scored Questionnaire to Identify Individuals with Chronic Kidney Disease in a Community-based Screening Program in Rural North Carolina.

Harward DH, Bang H, Hu Y, Bomback AS, Kshirsagar AV.

J Community Med Health Educ. 2014 Apr;4(Suppl 2):007. doi: 10.4172/2161-0711.S2-007. Epub 2014 Mar 28.

46.

Sodium phosphate does not increase risk for acute kidney injury after routine colonoscopy, compared with polyethylene glycol.

Layton JB, Klemmer PJ, Christiansen CF, Bomback AS, Baron JA, Sandler RS, Kshirsagar AV.

Clin Gastroenterol Hepatol. 2014 Sep;12(9):1514-21.e3. doi: 10.1016/j.cgh.2014.01.034. Epub 2014 Jan 29.

47.

Sickle trait in African-American hemodialysis patients and higher erythropoiesis-stimulating agent dose.

Derebail VK, Lacson EK Jr, Kshirsagar AV, Key NS, Hogan SL, Hakim RM, Mooney A, Jani CM, Johnson C, Hu Y, Falk RJ, Lazarus JM.

J Am Soc Nephrol. 2014 Apr;25(4):819-26. doi: 10.1681/ASN.2013060575. Epub 2014 Jan 23.

48.

Intravenous iron supplementation practices and short-term risk of cardiovascular events in hemodialysis patients.

Kshirsagar AV, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, Brookhart MA.

PLoS One. 2013 Nov 1;8(11):e78930. doi: 10.1371/journal.pone.0078930. eCollection 2013.

49.

The reply.

Kshirsagar AV, Brookhart MA.

Am J Med. 2013 Nov;126(11):e29. doi: 10.1016/j.amjmed.2013.07.010. No abstract available.

PMID:
24157299
50.

Opioid use in the US hemodialysis population.

Butler AM, Kshirsagar AV, Brookhart MA.

Am J Kidney Dis. 2014 Jan;63(1):171-3. doi: 10.1053/j.ajkd.2013.09.008. Epub 2013 Oct 19. No abstract available.

Supplemental Content

Loading ...
Support Center